Clinical and Economic Benefit of Advanced Therapies for the Treatment of Active Ankylosing Spondylitis
Open Access
- 12 August 2023
- journal article
- research article
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 10 (5) , 1385-1398
Abstract
Introduction Recent changes to treatment guidelines for ankylosing spondylitis (AS) have listed first-line advanced therapies as tumor necrosis factor (TNF), interleukin (IL)-17, and Janus kinase (JAK) inhibitors. This study sought to assess the comparative clinical and economic benefit of advanced therapies approved for AS. Methods A systematic literature review was conducted to identify randomized clinical trials for JAK inhibitors (upadacitinib [UPA], tofacitinib [TOF]), anti-IL-17 therapies (secukinumab [SEC], ixekizumab [IXE]), and TNF inhibitors (adalimumab [ADA], etanercept [ETN], golimumab [GOL]) used for the treatment of active AS. Clinical efficacy was evaluated by Assessment of Spondyloarthritis International Society 40 (ASAS40) criteria and treatment discontinuation due to adverse events (AEs) was used to generate response rates synthesized via a Bayesian network meta-analysis. Number needed to treat (NNT) was calculated as the reciprocal of incremental response rate of each treatment versus placebo. Cost per ASAS40 responder (CPR) was calculated as the 12-week treatment costs divided by ASAS40 response rates. Data were stratified by biologic treatment status (i.e., biologic naïve [bio-naïve] or inadequate response or intolerance to biologics [bio-IR]) for efficacy and CPR analyses. Results Among bio-naïve patients, the response rate for ASAS40 was 53.6% for UPA-treated patients, whereas most other treatments had response rates between 41% and 49%. NNTs were lowest for UPA-treated patients at 2.8 (other therapies 3.2–4.8). Estimated CPR among UPA-treated patients was lowest (UPA $39.5k vs others $44.2k–102.5k). Efficacy and CPR trends were similar among bio-IR and TNF-IR patients. Among bio-naïve and bio-IR patients, the rate of AEs leading to discontinuation was lowest among UPA and SEC-treated patients (0.0, others 0.6–3.7%). Conclusions Relative to other treatments assessed in this study, UPA demonstrated numerically greater clinical and economic benefit for the treatment of AS. Head-to-head or real-world comparisons of these therapies are warranted and may inform clinical decision-making.Keywords
Funding Information
- AbbVie
This publication has 15 references indexed in Scilit:
- Predicting response to anti-TNFα therapy among patients with axial spondyloarthritis (axSpA): results from BSRBR-ASRheumatology, 2020
- A cost per responder analysis of secukinumab vs adalimumab for the treatment of ankylosing spondylitis from the Korean perspectiveInternational Journal of Rheumatic Diseases, 2019
- 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial SpondyloarthritisArthritis Care & Research, 2019
- Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing SpondylitisRheumatology and Therapy, 2019
- Network Meta‐Analysis for Decision Making2018
- Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritisSeminars in Arthritis and Rheumatism, 2017
- Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-α and Interleukin Inhibitors in the Treatment of Active Ankylosing SpondylitisRheumatology and Therapy, 2016
- ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritisRheumatology, 2015
- Heterogeneity: Subgroups, Meta-Regression, Bias And Bias-Adjustment2012
- EVALUATION OF DIAGNOSTIC CRITERIA FOR ANKYLOSING SPONDYLITIS: A COMPARISON OF THE ROME, NEW YORK AND MODIFIED NEW YORK CRITERIA IN PATIENTS WITH A POSITIVE CLINICAL HISTORY SCREENING TEST FOR ANKYLOSING SPONDYLITISRheumatology, 1985